STING is a critical component of host innate immune defense to viruses, but can also contribute to chronic autoimmune or autoinflammatory disease. Once activated, the cGAS-STING pathway induces both type I IFN expression and NF-kB-mediated cytokine production. Currently these two signaling arms are thought to be mediated via the upstream kinase, TANK-binding kinase 1 (TBK1). Recent work highlights that NF-kB, rather than type I IFN, may play a major role in the pathology derived from STING activation in vivo. Whilst the mechanism to induce type I IFNs downstream of STING are well understood, how STING elicits NF-kB activation remains poorly described. Here, using pharmacological and genetic approaches we show that TBK1 alone is not required for STING-induced NF-kB-dependent cytokine production in human and mouse immune cells, as well as in vivo. Our results redefine the signaling events downstream of cGAS-STING, providing significant insight into the potential limitations of TBK1 inhibition in the clinic. Furthermore, they suggest that cGAS-STING will need to be targeted directly to effectively ameliorate the inflammation underpinning chronic immune disorders associated with STING hyperactivity.